drugset / Trial / NCT03263533
HDAC Inhibitor Augmentation to Clozapine
RandomizedCrossoverQuadruple-blindTreatment
Summary
The main goal of this pilot study is to test the extent to which adjunctive treatment with the histone deacetylase (HDAC) inhibitor vorinostat improves brain plasticity and cognition in a pilot placebo-controlled trial in patients with schizophrenia who are on clozapine.
Timeline
- Start
- 2017-04
- Primary completion
- 2019-02
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 300 mg | Oral |